France
DNA Script is set on a transformative path in the biotechnology sector, particularly impacting molecular biology and personalized medicine. Founded in 2014 and headquartered in France, this company aims to redefine DNA synthesis through innovative enzymatic methods.
Their primary product, SYNTAX™️, positions them at the forefront of genomic research, offering a benchtop DNA printer powered by enzymatic technology. This innovation marks a significant leap in enzyme engineering and surface and nucleotide chemistries, which are critical for advancements in synthetic biology and health care.
DNA Script's vision has attracted substantial financial backing, evidenced by their recent $35.00M Series C investment received on 01 January 2022 from notable investors such as T. Rowe Price, Baillie Gifford, eureKARE, Healthcor Management, and Irving Investors. Positioned within the biotechnology, health care, and life sciences industries, DNA Script remains a compelling opportunity for those investing in groundbreaking genomic technologies.
